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Introduction 
Every day, millions of Americans prick their fingertips, feed blood into a glucose 
meter, and adjust their diet in a ritual to stay healthy. This is the diabetic way of 
life, what many older diabetics call having the “sweet blood.” 1 And it has become 
an American way of life, affecting about one in ten people with rates among 
minorities and the poor in double-digit percentages. The complications are serious 
and deadly—neuropathy, blindness, cardiovascular disease, and renal failure—
with total costs around $245 billion for 2014 alone. Dr. Frank Vinicor, former 
American Diabetes Association president, has called diabetes “the Rodney 
Dangerfield of diseases”: expensive to treat, hard to manage, and easy to ridicule.2  
 
Sweet Blood explores how today’s scourge stems from how Americans have 
defined, studied, shaped, and been reshaped in turn by their environment. From 
the Gilded Age to the present day, diabetes has embodied fears over controlling 
and mastering our bodies and our surroundings. It has altered relationships 
between farm and table, influenced diets and nutritional guidelines, intensified 
obsessions to quantify our bodies, bolstered reliance upon technology to prolong 
life, and reinforced differences between one another and the natural world that 
enfolds us.  
 
To unravel the tangled history of diabetes, Sweet Blood draws from scholarship in 
four distinct but interrelated fields to advance an expanded role for the 
environment in human history. First, environmental historians have shown how 
microbes, animals, weather, and other forces of nature act upon history by 
reinforcing or limiting human agency. Second, historians of medicine have 
connected race, gender, class, and place to rethink how illness and social inequities 
connect. Third, science and technology studies scholars emphasize how scientific 
knowledge emerges from physical engagement with physical nature in particular 
spaces. Finally, social epidemiologists have pooled methodologies from the 
humanities, social sciences, and biomedicine to locate the historical origins and 
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geographic distribution of health inequalities. To paraphrase historian Gregg 
Mitman, diabetes, as with other ailments, is “not a thing but a relation…a way of 
being in the world that changes in both place and time.”3 
 
Building upon this scholarship, Sweet Blood examines how ideas and practices 
about health entwine with material changes to shape entire landscapes and 
individual bodies. It traces how concepts of risk and environment have created 
ambient dread over perpetual threats to our wellbeing. Yet despite their ubiquity, 
chronic illnesses are scarce in historical literature when compared to studies on 
communicable diseases. Moreover, many humanities scholars still overlook the 
vital role of physical nature in shaping diseases as cultural phenomena. Sweet 
Blood reframes chronic disease as environmental history. 
 
One note: while physicians have classified two major types of diabetes—type 1, also 
called “insulin-dependent” or “juvenile onset” diabetes, often diagnosed in the 
young, and type 2 or “adult onset” or “insulin resistant,” the more common variant 
associated with advancing age or obesity—my book focuses mostly but not fully on 
type 2 diabetes. Indeed, as the book reveals, these typologies are cultural and 
environmental artifacts for a common disease that alters how the body produces 
and uses insulin, the hormone that helps cells to metabolize glucose, a main source 
of fuel. Given these broad similarities as well as common therapies, Sweet Blood 
chronicles both variants in one narrative. 
 
The goal of my research at the Rockefeller Archive Center in March 2017 was to 
explore the role of private philanthropy in shaping political and scientific 
responses to the growing problem of diabetes in twentieth-century North America. 
Three broad questions directed my research: 1.) what role did the early Rockefeller 
Foundation play in making insulin widely available and affordable in the interwar 
period; 2.) how did the Rockefeller family, through its foundations and the 
Rockefeller Institute for Medical Research (later Rockefeller University), support 
as well as reshape biomedical research diabetes etiology of; and 3.) how did the 
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Rockefeller Foundation, Commonwealth Fund, and other private philanthropies 
help to raise awareness of chronic diseases as a major public health threat in 
postwar North America? 
 
My one-week research trip to the Rockefeller Archive Center revealed the 
important roles that the Rockefeller organizations and other private 
philanthropies played in shaping the political, scientific, and cultural landscapes 
of chronic disease. What follows are some preliminary assessments of how my 
research at the RAC will shape my larger book-in-progress. 
 
The “Miracle” of Insulin and Early 
Research on Diabetes 
 
In late 1921, a group of scientist-physicians at the University of Toronto discovered 
what historian Michael Bliss has called “one of the genuine miracles of modern 
medicine”—the discovery of insulin.4 Before insulin, juvenile diabetics, living with 
what we now call type 1 diabetes, died young. Insulin converted a once fatal disease 
into a manageable condition.5 As news of the breakthrough in Toronto spread 
across the world, physicians and their diabetic patients clamored to receive the 
new therapy quickly and at affordable prices. 
 
The Rockefeller Foundation played a pivotal role in helping to meet demand for 
insulin. Indeed, the Rockefeller organizations had already taken an interest in 
basic biomedical research. Diabetes was one of many ailments that attracted 
attention, thanks in large part to the work of the first director of the Rockefeller 
Institute for Medical Research, Simon Flexner. Prior to the discovery of insulin, 
the RIMR, at Flexner’s urging, had supported the research of Dr. Frederick 
Madison Allen, who had been appointed to a position in 1914 based on his research 
linking caloric-restricted diets and diabetes treatment. With RIMR support, Allen 
published the summary of his dietary guidelines in a 1919 report.6 Allen’s often-
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brutal treatment, which limited patients to as little as 400 calories per day, was 
accepted as the most effective way to extend the life of juvenile (or type 1) diabetics 
until the widespread availability of injectable insulin. It was also a controversial 
treatment, leaving patients emaciated and weakened, often only extending their 
lives by a few short, starved years.7 Allen would eventually leave the RIMR in 1921 
to open the Physiatric Institute in Morristown, New Jersey, but relied upon 
support, at first, from the Rockefeller organizations to keep his clinic open for the 
first six years of operation.8 
 
But it was the Rockefeller’s “Insulin Gift” that put the stamp of private 
philanthropic approval on the revolutionary new therapy to treat diabetes. One of 
Allen’s own patients, Elizabeth Hughes, daughter of U.S. Secretary of State Charles 
Evans Hughes, was one of the first to be treated with insulin by one of the co-
discoverers in Toronto, Frederick Banting. When Allen visited Hughes in Toronto 
three months after her treatment, he was amazed by the change in her health.9 
Before Hughes visited Toronto, however, her well-connected and worried father 
had already written to Rockefeller about the miraculous new therapy.10 As director 
of the RIMR, Flexner had also taken notice of insulin and its healing powers. So, 
too, had Frederick T. Gates, the Baptist clergyman who in 1891 had become the 
principal business and philanthropic advisor to John D. Rockefeller, Sr. As many 
observers have noted, without Gates, the many Rockefeller philanthropies may 
have never succeeded. Gates was himself a diabetic. Together with Flexner, they 
encouraged Rockefeller family to throw their financial and political weight behind 
making insulin the new standard of diabetic care.11  
 
On June 20, 1923, the Rockefeller Institute announced a $150,000 gift to 
distribute insulin to fifteen hospitals in the United States and Canada. In addition 
to funding insulin supplies, the gift also provided for educating physicians and 
patients on how to use insulin properly and safely. As Flexner noted, the 
Rockefeller gift was based on sound evidence. “There are no two minds about it,” 
he said, “it works.”12 Elliott P. Joslin, who was the leading specialist in diabetes 
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clinical treatment, noted that “a most liberal portion was donated to Boston” where 
it was invaluable in preventing “needless deaths from diabetic coma.”13 He and 
other physicians, including Frederick Allen, congratulated the Rockefellers on 
using their immense wealth to distribute insulin as widely, quickly, and 
inexpensively as possible.14 
 
While the Rockefeller “insulin gift” was a one-time only contribution, the archival 
evidence, when coupled with further research in newspapers and medical 
periodicals, underscores its significance in the history of chronic disease 
treatment. In terms of simple monetary value, the gift was enormous. But if 
measured in terms of political and cultural capital, it helped to bolster the 
importance of insulin as a new and reliable therapy. As many scholars have argued, 
insulin was far from a panacea. As diabetics lived longer, they faced more 
complications over time. 15 Nevertheless, the Rockefeller “insulin gift” helped to 
make the miracle of Toronto an everyday blessing for millions. 
 
Biomedical Research on Diabetes, 
Metabolism, and Endocrinology 
After the “Insulin Gift” 
 
In a 1933 article, Elliott Joslin, together with his co-authors, Louis Dublin, a former 
statistician and current vice president at the Metropolitan Life Insurance 
Company, and Herbert H. Marks, a new statistician at Met Life, argued that 
diabetes was had “become a disease of major importance” that was on the increase. 
Ten years after the Rockefeller insulin gift, the “amazing progress that has been 
made in its diagnosis and treatment has not stemmed the rising mortality from 
diabetes.”16 In subsequent years, the threat of diabetes to public wellbeing would 
only become more pronounced. Research at the Rockefeller Archive Center 
revealed that private philanthropic support for basic biomedical research on 
R A C  R E S E A R C H  R E P O R T S  7 
 
diabetes etiology, pathogenesis, treatment and prevention took several directions 
in the era after insulin. 
 
One direction was to fund research at various institutes and clinics to investigate 
the physiological and biochemical aspects of diabetes. In the early 1970s, the 
Rockefeller Brothers Fund gave a $15,000 grant to explore creating artificial beta 
cells, the portion of the pancreas responsible for the production of insulin. 17 
Likewise, at the Rockefeller University (formerly the Rockefeller Institute for 
Medical Research), scientists investigated the utility of biosynthetic human insulin 
produced from genetically-engineered E. coli bacteria. This type of insulin, first 
synthesized in the early 1980s, has all but replaced insulin derived from cattle and 
pig pancreases.18 Research on the physiology of the pancreas had antecedents, 
stretching back to the work by Eugene L. Opie, another former Rockefeller 
University researcher, who was credited for identifying the cause of diabetes as 
linked to damaging the part of the pancreas called the Islands of Langerhans, 
where insulin-producing beta cells reside. 
 
A second direction examined the interplay between human neurophysiology, 
endocrinology, and chronic diseases including diabetes. Again, the Rockefeller 
University played a principal role in this research project, led by faculty member 
Bruce S. McEwen, who earned his Ph.D. at Rockefeller in 1964 under the direction 
of molecular biologist Alfred Ezra Mirsky. Although much of McEwen’s papers 
remain in his possession—he currently directs the Harold and Margaret Milliken 
Hatch Laboratory of Neuroendocrinology at Rockefeller University—available 
materials point to how his early investigations into stress and human health have 
helped to redefine understandings of behavior and hormonal regulation. In 
particular, McEwen’s research into allostatic load—the accumulation of chronic or 
repeated stress that triggers increased neuroendocrine responses—suggests that 
diabetes may not be caused entirely by excessive caloric intake or insufficient 
exercise. Put another way, certain environmental stressors over time could literally 
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get under the skin to produce ill health: cardiovascular disease, immune disorders, 
and diabetes, to name just three.19 
 
A final direction was more diffuse but also more intriguing in light of my own 
project on the environmental history of diabetes—the connections between large-
scale environmental change and definitions of human and ecological health. The 
leading scientist in this vein was René Jules Dubos, the French-born 
microbiologist and pathologist who spent his entire career at the Rockefeller 
University. Although Dubos spent his scientific career focused on microbial 
diseases, particularly developing effective antibiotics and solutions to the 
mounting problem of antibiotic resistance, he was also interested in the 
relationship between human wellbeing and environmental change. As Dubos 
wrote in his well-known The Mirage of Health, first published in 1961, “complete 
freedom from disease and from struggle is almost incompatible with the process of 
living.” 20  The archival materials at the Rockefeller Archive Center suggest an even 
more complex view of the interplay between individual health and ecological 
context. As he wrote in an undated draft of notes for a possible talk or article, 
modern humans “have to learn to trust in the resiliency of our physical and 
psychological nature.” 21  Dubos suggested that the boundaries between human 
bodies and their environments, between nature as material and human nature as 
psychological, are more malleable than modern medicine might assume. 
 
Dubos’s observations emphasize that health is less of a static state of being than a 
continuum—an important insight for reinterpreting chronic diseases within the 
framework of environmental history. 
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Public Health and Chronic 
Disease: Surveillance and 
Prevention 
 
In a 1946 address to the American Public Health Association annual meeting in 
Cleveland, Hugh L.C. Wilkerson, a surgeon for the U.S. Public Health Service, gave 
a dire warning. In 1900, diabetes was the twenty-fifth ranked cause of death in the 
nation; by 1940, it had jumped to ninth place. With an aging population freed of 
war or economic depression, he expected diabetes to climb higher on the grim list. 
Given that diabetes was “amenable to definite methods of control” based upon 
prevailing science, he called for “concerted action” to address this public health 
menace before it became an epidemic.22 
 
As with infectious and vector-borne diseases in the United States and abroad, the 
Rockefeller organizations and other private philanthropies helped to fund and 
shape public health efforts to track and prevent chronic disease. According to 
historian George Weisz, an expanding awareness of chronic disease during the 
twentieth century coevolved with expanding state capacity and authority to define 
and address health on a national scale. 23  Yet central to this expanding state 
authority and capacity were private foundations who funded many of the early 
efforts at surveillance as well as publicizing efforts at prevention. As early as the 
1930s, the Rockefeller Foundation and the Commonwealth Fund co-funded 
chronic disease surveys in New York City, which had one of the nation’s most 
vigorous programs.24 
 
But as my research at the Rockefeller Archive Center revealed, while New York City 
may have been one pacesetter, Gotham was far from the only place innovating in 
the study and prevention of chronic diseases such as diabetes. During the 1950s, 
the Rockefeller Foundation gave grants and other assistance to statewide programs 
in California. Led by Lester Breslow, a physician and public health scientist who 
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led the Bureau of Chronic Diseases of the California Department of Public Health 
from 1945 to 1960, the campaign to track and prevent chronic diseases relied upon 
“multiphasic screening” to test for numerous chronic diseases, including diabetes. 
Researchers fanned out across what was becoming the nation’s most populous 
state, conducting interviews and administering tests in small rural communities 
and large urban neighborhoods alike. John B. Grant, the associate director for the 
Public Health Division at the Rockefeller Foundation, spent several months in the 
field with Breslow and his team during the mid-1950s, writing reports lauding the 
California approach.25 
 
By this time, chronic disease had become an issue of national importance. The 
Commission on Chronic Illness (CCI), initially launched as an interim committee 
in November 1948, received “small sums” the following year from the Rockefeller 
Foundation as well as several insurance companies, the pharmaceutical company 
Eli Lilly and Company, and The Johns Hopkins University. Larger donors include 
the Commonwealth Fund, the U.S. Public Health Service, and the American 
Medical Association.26 As the first national initiative to investigate chronic disease, 
the CCI convened experts from a wide slate of medical and public health specialties 
to address both prevention and long-term care. Dissolved in 1956, the CCI during 
its lifetime produced a four-volume report as well as a monthly newsletter. 
Archival documents from the Rockefeller Archive Center illuminate how the 
Commonwealth Fund in particular supported two CCI community-based surveys 
in Baltimore, Maryland and Hunterdon, New Jersey.27 
 
Materials from the Rockefeller Archive Center suggest that private philanthropic 
support elevated the importance of chronic disease as a public health concern in 
the early postwar era. While local, state, and federal agencies played essential roles 
in defining, tracking, and addressing chronic diseases, they often received 
substantial financial and logistical support from private foundations. The health 
concerns of the state often mirrored the health concerns of the philanthropic 
sector. This union of shared interests may have helped to sculpt the terrain in 
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subsequent years for later public-private partnerships in the quest to improve the 
health of the nation. 
 
Conclusion 
Research at the Rockefeller Archive Center provided critical documentation on the 
role that private philanthropy played in addressing diabetes as a major public 
health problem in the twentieth century. Beginning with the dramatic discovery of 
insulin through the slow but steady increase of diabetes as a leading cause of death, 
private foundations provided needed financial and administrative support. As I 
argue in the larger book project, diabetes is a mirror of modernity, reflecting how 
changing economic, social, and most importantly environmental relationships 
have generated conditions for chronic illnesses to thrive and spread. Records from 
private philanthropic organizations and research centers—the Rockefeller 
Foundation, the Commonwealth Fund, the Rockefeller Institute for Medical 
Research and the Rockefeller University—support my argument that philanthropic 
institutions are part of this story.  
 
Sweet Blood is a history of our modern world. It is a story that connects the 
personal to the public through our connections to the environment and one 
another. It asks us to rethink the connection between human nature and nature. It 
compels us to confront a major health problem anew. “Acting like a sponge,” writes 
physician-anthropologist Arthur Kleinman, diabetes, like other chronic ailments, 
“soaks up personal and social significance from the world.”28 In diabetes lies the 
modern nature of health.  
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